Pfizer Inc. will ship only half of the COVID-19 vaccine doses it originally planned due to logistical problems, the Wall Street Journal reported on Thursday.
"Scaling up the raw material supply chain took longer than expected. And it's important to highlight that the outcome of the clinical trial was somewhat later than the initial projection," a spokesperson for the company told the news organization.
Another source claimed that "some early batches of raw materials failed to meet the standards," causing a delay before they were fixed. However, the company still expects to deliver more than one billion doses next year.
Pfizer's shares were down 2.55% following the report.
